{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:45:31Z","timestamp":1782819931998,"version":"3.54.5"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Shanghai Eastern Talents Program","award":["BJKJ2025016"],"award-info":[{"award-number":["BJKJ2025016"]}]},{"name":"China Antimicrobial Surveillance Network"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["2018QD100"],"award-info":[{"award-number":["2018QD100"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Antimicrobial Surveillance Network","award":["3030231003"],"award-info":[{"award-number":["3030231003"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study comprehensively evaluates the in vitro antibacterial activity of eravacycline against a wide range of significant Gram-negative and Gram-positive bacteria collected across China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 1250 non-duplicate clinical isolates representing 12 genera and 21 species were collected from 40 hospitals between 2017 and 2019 across China. Minimal inhibitory concentrations were determined using the broth microdilution method in accordance with the standards set by the Clinical and Laboratory Standards Institute.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eravacycline demonstrated potent in vitro activity against most tested bacterial species. The MIC90 values ranged from 0.25 to 2\u2005mg\/L for Enterobacterales, except for Proteus vulgaris (4\u2005mg\/L). According to the FDA breakpoints, Escherichia coli and Klebsiella pneumoniae exhibited susceptibility rates of 98.9% and 70.9%, respectively. Eravacycline achieved an MIC90 value of 1\u2005mg\/L against Acinetobacter baumannii, which was the lowest among all agents tested. For Gram-positive isolates, eravacycline displayed MIC90 values of 0.5\u2005mg\/L for MRSA and methicillin-resistant CoNS (MRCNS), 0.03\u2005mg\/L for vancomycin-resistant Enterococcus faecium and 0.03\u2005mg\/L for Streptococcus pneumoniae, surpassing or equalling tigecycline and markedly outperforming doxycycline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This large-scale multicentre surveillance study demonstrated that eravacycline exhibited potent in vitro activity against major multidrug-resistant Gram-negative and Gram-positive pathogens, indicating that it could be a promising therapeutic option for treating infections caused by these strains.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlag077","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T11:44:37Z","timestamp":1777031077000},"source":"Crossref","is-referenced-by-count":0,"title":["<i>In vitro<\/i>\n                    activity of eravacycline and comparator agents against Gram-negative and Gram-positive bacteria: results from China Antimicrobial Surveillance Network between 2017 and 2019"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9171-8280","authenticated-orcid":false,"given":"Hongjian","family":"Ou","sequence":"first","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University , Shanghai ,","place":["China"]},{"name":"Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University , Shanghai ,","place":["China"]},{"name":"Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siquan","family":"Shen","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University , Shanghai ,","place":["China"]},{"name":"Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health , Shanghai ,","place":["China"]},{"name":"Department of Clinical Microbiology, Joint Laboratory of Hospital & Enterprise for Pathogen Diagnosis of Drug-Resistant Bacterial Infections and Innovative Drug R&D , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1436-3668","authenticated-orcid":false,"given":"Li","family":"Ding","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University , Shanghai ,","place":["China"]},{"name":"Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health , Shanghai ,","place":["China"]},{"name":"Department of Clinical Microbiology, Joint Laboratory of Hospital & Enterprise for Pathogen Diagnosis of Drug-Resistant Bacterial Infections and Innovative Drug R&D , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Yin","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University , Shanghai ,","place":["China"]},{"name":"Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renru","family":"Han","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University , Shanghai ,","place":["China"]},{"name":"Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fupin","family":"Hu","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University , Shanghai ,","place":["China"]},{"name":"Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health , Shanghai ,","place":["China"]},{"name":"Department of Clinical Microbiology, Joint Laboratory of Hospital & Enterprise for Pathogen Diagnosis of Drug-Resistant Bacterial Infections and Innovative Drug R&D , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"2026063005514839100_dlag077-B1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3390\/microorganisms7060159","article-title":"The role of minocycline in the treatment of nosocomial infections caused by multidrug, extensively drug and pandrug resistant Acinetobacter baumannii: a systematic review of clinical evidence","volume":"7","author":"Fragkou","year":"2019","journal-title":"Microorganisms"},{"key":"2026063005514839100_dlag077-B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101095","article-title":"Molecular and clinical epidemiology of carbapenem resistant Acinetobacter baumannii, Pseudomonas aeruginosa and enterobacterales in Fiji: a multicentre prospective observational study","volume":"47","author":"Baleivanualala","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"2026063005514839100_dlag077-B3","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1080\/14787210.2024.2408746","article-title":"Recent updates in treating carbapenem-resistant infections in patients with hematological malignancies","volume":"22","author":"Aslan","year":"2024","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026063005514839100_dlag077-B4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S1473-3099(22)00811-8","article-title":"Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis","volume":"23","author":"Willems","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026063005514839100_dlag077-B5","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3390\/antibiotics10060680","article-title":"Prevalence and risk factors for multidrug-resistant organisms colonization in long-term care facilities around the world: a review","volume":"10","author":"Rodr\u00edguez-Villodres","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2026063005514839100_dlag077-B6","author":"World Health Organization"},{"key":"2026063005514839100_dlag077-B7","doi-asserted-by":"publisher","DOI":"10.1128\/mSystems.00360-21","article-title":"Computational model to quantify the growth of antibiotic-resistant Bacteria in wastewater","volume":"6","author":"Sutradhar","year":"2021","journal-title":"mSystems"},{"key":"2026063005514839100_dlag077-B8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212029","article-title":"A decade of antimicrobial resistance in Staphylococcus aureus: a single center experience","volume":"14","author":"Vicetti Miguel","year":"2019","journal-title":"PLoS One"},{"key":"2026063005514839100_dlag077-B9","author":"China Antimicrobial Surveillance Network"},{"key":"2026063005514839100_dlag077-B10","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2317915","article-title":"ESKAPE in China: epidemiology and characteristics of antibiotic resistance","volume":"13","author":"Luo","year":"2024","journal-title":"Emerg Microbes Infect"},{"key":"2026063005514839100_dlag077-B11","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01650-22","article-title":"Multicenter clinical evaluation of ETEST eravacycline for susceptibility testing of Enterobacteriaceae and enterococci","volume":"61","author":"Blanchard","year":"2023","journal-title":"J Clin Microbiol"},{"key":"2026063005514839100_dlag077-B12","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s15010-021-01709-3","article-title":"Antibiotics in the pipeline: a literature review (2017-2020)","volume":"50","author":"Al-Tawfiq","year":"2022","journal-title":"Infection"},{"key":"2026063005514839100_dlag077-B13","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1128\/AAC.01614-13","article-title":"Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections","volume":"58","author":"Solomkin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026063005514839100_dlag077-B14","author":"CLSI"},{"key":"2026063005514839100_dlag077-B15","author":"US Food and Drug Administration"},{"key":"2026063005514839100_dlag077-B16","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"2026063005514839100_dlag077-B17","author":"CLSI"},{"key":"2026063005514839100_dlag077-B18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.935343","article-title":"The efficacy and safety of eravacycline compared with current clinically common antibiotics in the treatment of adults with complicated intra-abdominal infections: a Bayesian network meta-analysis","volume":"9","author":"Meng","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2026063005514839100_dlag077-B19","doi-asserted-by":"publisher","first-page":"S565","DOI":"10.1093\/cid\/ciz830","article-title":"Treatment options for carbapenem-resistant Gram-negative bacterial infections","volume":"69","author":"Doi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026063005514839100_dlag077-B20","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025387","article-title":"Tetracycline antibiotics and resistance","volume":"6","author":"Grossman","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026063005514839100_dlag077-B21","article-title":"In vitro activity of eravacycline against Gram-negative Bacilli isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026063005514839100_dlag077-B22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jgar.2024.03.014","article-title":"Antimicrobial activity of eravacycline and other comparative agents on aerobic and anaerobic bacterial pathogens in Taiwan: a clinical microbiological study","volume":"37","author":"Tsai","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"key":"2026063005514839100_dlag077-B23","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jgar.2023.04.017","article-title":"In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020","volume":"33","author":"Hawser","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"2026063005514839100_dlag077-B24","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1504013","article-title":"In vitro activities of eravacycline against clinical bacterial isolates: a multicenter study in Guangdong, China","volume":"15","author":"Liao","year":"2024","journal-title":"Front Microbiol"},{"key":"2026063005514839100_dlag077-B25","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.2147\/IDR.S396910","article-title":"Antibacterial activity of eravacycline against carbapenem-resistant Gram-negative isolates in China: an in vitro study","volume":"16","author":"Zou","year":"2023","journal-title":"Infect Drug Resist"},{"key":"2026063005514839100_dlag077-B26","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaf153","article-title":"AMRrounds: susceptibility to the new tetracycline-derivative eravacycline of New Delhi metallo-\u03b2-lactamase-producing Klebsiella pneumoniae complex","volume":"7","author":"Galfo","year":"2025","journal-title":"JAC Antimicrob Resist"},{"key":"2026063005514839100_dlag077-B27","doi-asserted-by":"publisher","DOI":"10.2174\/1874467217666230331081434","article-title":"Antimicrobial resistance of clinical Klebsiella pneumoniae isolates: involvement of AcrAB and OqxAB efflux pumps","volume":"17","author":"Albarri","year":"2024","journal-title":"Curr Mol Pharmacol"},{"key":"2026063005514839100_dlag077-B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41426-017-0002-0","article-title":"Overexpression of OqxAB and MacAB efflux pumps contributes to eravacycline resistance and heteroresistance in clinical isolates of Klebsiella pneumoniae","volume":"7","author":"Zheng","year":"2018","journal-title":"Emerg Microbes Infect"},{"key":"2026063005514839100_dlag077-B29","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.3390\/pathogens14121214","article-title":"Resistance of Gram-negative Bacteria to eravacycline: a systematic review of data from in vitro studies","volume":"14","author":"Falagas","year":"2025","journal-title":"Pathogens"},{"key":"2026063005514839100_dlag077-B30","doi-asserted-by":"publisher","first-page":"16581","DOI":"10.1038\/s41598-025-98206-6","article-title":"Emergence of transferable tigecycline and eravacycline resistance gene tet(X4) in Escherichia coli isolates from Iran","volume":"15","author":"Haeili","year":"2025","journal-title":"Sci Rep"},{"key":"2026063005514839100_dlag077-B31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40265-019-01067-3","article-title":"Eravacycline: a review in complicated intra-abdominal infections","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"key":"2026063005514839100_dlag077-B32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1055\/s-0034-1398388","article-title":"Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options","volume":"36","author":"Doi","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"2026063005514839100_dlag077-B33","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1093\/ofid\/ofw172.1373","article-title":"In vitro global surveillance of eravacycline and comparators against Enterobacteriaceae, Acinetobacter baumannii, Stenotrophomonas maltophilia, including multidrug-resistant (MDR) isolates, over a 3-year period (2013\u20132015)","volume":"3","author":"Bassetti","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2026063005514839100_dlag077-B34","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1356353","article-title":"Emergence of eravacycline heteroresistance in carbapenem-resistant Acinetobacter baumannii isolates in China","volume":"14","author":"Li","year":"2024","journal-title":"Front Cell Infect Microbiol"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/3\/dlag077\/68297134\/dlag077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/3\/dlag077\/68297134\/dlag077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:54:03Z","timestamp":1782816843000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlag077\/8679295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlag077","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,4,30]]},"article-number":"dlag077"}}